Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 22c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.06), $0.22 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $17.33 million.

Cash and cash equivalents were $78.3 million as of March 31, 2016.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Morgan Stanley refreshes Strait of Hormuz reopening analysis
• General Mills beats estimates as cost savings offset volumes